These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Yang A; Li M; Fang M Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597 [No Abstract] [Full Text] [Related]
3. Drug Discovery by Targeting Mutant KRAS. Ye N Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422 [No Abstract] [Full Text] [Related]
4. KRAS: From undruggable to a druggable Cancer Target. Uprety D; Adjei AA Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246 [TBL] [Abstract][Full Text] [Related]
5. Direct KRAS inhibition: progress, challenges, and a glimpse into the future. Grapsa D; Syrigos K Expert Rev Anticancer Ther; 2020 Jun; 20(6):437-440. PubMed ID: 32320301 [No Abstract] [Full Text] [Related]
6. Progress in targeting RAS with small molecule drugs. McCormick F Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085 [TBL] [Abstract][Full Text] [Related]
7. Cracking KRAS. Mullard A Nat Rev Drug Discov; 2019 Nov; 18(12):887-891. PubMed ID: 31780856 [No Abstract] [Full Text] [Related]
8. Targeting the MAPK Pathway in KRAS-Driven Tumors. Drosten M; Barbacid M Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276 [TBL] [Abstract][Full Text] [Related]
9. KRAS-targeted therapies in advanced solid cancers: drug the undruggable? Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378 [No Abstract] [Full Text] [Related]
10. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue. Perurena N; Cichowski K Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932 [TBL] [Abstract][Full Text] [Related]
11. Targeting the KRAS G12C mutation in patients with advanced solid tumors. Hong DS Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163 [No Abstract] [Full Text] [Related]
12. [KRASG12C mutation is not undruggable anymore]. Rodrigues M Bull Cancer; 2020 Feb; 107(2):145. PubMed ID: 31955868 [No Abstract] [Full Text] [Related]
13. KRAS Alleles: The Devil Is in the Detail. Haigis KM Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387 [TBL] [Abstract][Full Text] [Related]
14. Targeting Mutant KRAS for Anticancer Therapy. Chen F; Alphonse MP; Liu Y; Liu Q Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898 [TBL] [Abstract][Full Text] [Related]
15. Covalent inhibitors of the GTPase KRAS Kettle JG; Cassar DJ Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776 [No Abstract] [Full Text] [Related]
16. KRAS Cagir A; Azmi AS Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867 [No Abstract] [Full Text] [Related]
17. KRAS: A Promising Therapeutic Target for Cancer Treatment. Wu HZ; Xiao JQ; Xiao SS; Cheng Y Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755 [TBL] [Abstract][Full Text] [Related]
18. PIP5K1A: a potential target for cancers with KRAS or TP53 mutations. East MP; Laitinen T; Asquith CRM Nat Rev Drug Discov; 2020 Jul; 19(7):436. PubMed ID: 32332925 [No Abstract] [Full Text] [Related]
19. Covalent targeting of acquired cysteines in cancer. Visscher M; Arkin MR; Dansen TB Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855 [TBL] [Abstract][Full Text] [Related]
20. Ras proteins as therapeutic targets. Chakraborty A; Linnane E; Ross S Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]